Overview A Phase 2b Study of Icosabutate in Fatty Liver Disease Status: Recruiting Trial end date: 2023-01-30 Target enrollment: Participant gender: Summary A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis Phase: Phase 2 Details Lead Sponsor: NorthSea Therapeutics B.V.